NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 14th March 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Anna Pracz Present for all items
4. Dr Alistair Patton Items 1.1 to 4.2.2
5. Dr Andrew Makin Present for all items
6. Dr Bushra Hasnie Present for all items
7. Dr Daniel Gallacher Present for all items
8. Dr Francis Drobniewski Present for all items
9. Dr Mark Tanner Present for all items
10. Dr Natalia Kunst Present for all items
11. Dr Stuart Williams Present for all items
12. Dr Toby Smith Present for all items
13. Dr Veline L’Esperance Present for all items
14. Gabriel Rogers  Present for all items
15. Lisa Attrill Present for all items
16. Nigel Westwood Present for all items
17. Professor David McAllister Present for all items
18. Tony Wootton Present for all items

NICE staff (key players) present

Rich Diaz, Associate Director Present for all items

Vonda Murray, Project Manager Present for all items

Joanna Richardson, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Anna Willis, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Sm Hasan ul Bari, Topic Associate Analyst Items 1.1 to 4.2.2

Zoe Charles, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Ross Wilkinson, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Wajeeha Asim, Administrator, Technology Appraisals Present for all items

External assessment group representatives present

Thenmalar Vadiveloo, Aberdeen HTA Group Items 1.1 to 4.1.3

Graham Scotland, Aberdeen HTA Group Items 1.1 to 4.1.3

Matt Stevenson, School of Health and Related Research (ScHARR)

Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Ceri Bygrave, Consultant Haematologist clinical expert, nominated by, UK Myeloma Society

Items 1.1 to 4.1.3

Gordon Cook, Professor of Haematology clinical expert, nominated by, UK Myeloma Society Items 1.1 to 4.1.3

Scott Purdon, Patient expert, nominated by Myeloma UK Items 1.1 to 4.1.3

Jon Missin, Patient expert, nominated by Myeloma UK Items 1.1 to 4.1.3

Peter Clark, NHS CDF clinical lead Present for all items

Neil Rabin, Consultant Haematologist, clinical expert nominated by Sanofi UK

Items 5.1 to 5.1.3

Jonathan Sive, Consultant Haematologist, clinical expert nominated by Myeloma UK

Items 5.1 to 5.1.3

Caroline Donoghue, Patient Expert nominated by Myeloma UK

Items 5.1 to 5.1.3

Observers present

Milena Wobbe, Technical Analyst - Managed Access Items 1.1 to 5.1.3

Sarah Wilkes, Technical Adviser - Commercial Risk Assessment, Commercial Liaison

Present for all items

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Charles Crawley welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Peter Wheatley Price, Rhiannon Owen, Vanessa Danielson, Warren Linley, Hatim Abdulhussein.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 15th February 2024.

1. **Appraisal of Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]**
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10918).
      3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Nigel Westwood (lay), Toby Smith (clinical) and Gabriel Rogers (cost).
   2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10918>.

1. **Appraisal of Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]**
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Sanofi.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10979).
      3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Charles Crawley.
   2. Part 2 –Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10979>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 11th April and will start promptly at 9:00am.